ArticleInfection2015
Clinical and economic burden of community-acquired pneumonia in the Veterans Health Administration, 2011: a retrospective cohort study.
Article in Infection, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- The Epidemiological Trends of Hospitalized Pneumonia Patients in Taiwan in 2019 and 2020: A Population-based Nationwide Study.Journal of acute medicine · 2026Article
- Periodontitis and respiratory infections - exploring the oral-systemic link.Annals of medicine and surgery (2012) · 2026Article
- The effect of type 2 diabetes on the prognosis of community-acquired pneumonia.Frontiers in endocrinology · 2026Article
- A Sequent of Gram-Negative Co-Infectome-Induced Acute Respiratory Distress Syndrome Are Potentially Subtle Aggravators Associated to the SARS-CoV-2 Evolution of Virulence.Diagnostics (Basel, Switzerland) · 2024Article
- Disease burden and high-risk populations for complications in patients with acute respiratory infections: a scoping review.Frontiers in medicine · 2024Article
- Molecular and Source-Specific Profiling of HospitalMicroorganisms · 2023Article
- How and when to manage respiratory infections out of hospital.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Clinical and economic burden of pneumococcal disease among individuals aged 16 years and older in Germany.Epidemiology and infection · 2022Article
- Comparison between Ceftriaxone and Sulbactam-Ampicillin as Initial Treatment of Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2022Article
- Effectiveness of Beta-Lactam plus Doxycycline for Patients Hospitalized with Community-Acquired Pneumonia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Observational
- Systematic review and meta-analysis of comorbidities and associated risk factors in Indian patients of community-acquired pneumonia.SAGE open medicine · 2022Review
- Review
- Hospital Admission Patterns in Adult Patients with Community-Acquired Pneumonia Who Received Ceftriaxone and a Macrolide by Disease Severity across United States Hospitals.Antibiotics (Basel, Switzerland) · 2020Article
- Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.Open forum infectious diseases · 2020Article
- Household Costs Associated with Hospitalization of Children with Severe Pneumonia in Quito, Ecuador.The American journal of tropical medicine and hygiene · 2020Article
- Community-acquired pneumonia in critically ill very old patients: a growing problem.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Antibiotic Treatment Failure and Associated Outcomes Among Adult Patients With Community-Acquired Pneumonia in the Outpatient Setting: A Real-world US Insurance Claims Database Study.Open forum infectious diseases · 2020Article
- Accelerating the sustainable development goals through microbiology: some efforts and opportunities.Access microbiology · 2020Review
- Importance of Mcl-1 for Alveolar Macrophage Apoptosis-associated Bacterial Killing.American journal of respiratory and critical care medicine · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe burden of community-acquired pneumonia (CAP) is not well described in the US Veterans Health Administration (VHA).
methodsCAP was defined as having a pneumonia diagnosis with evidence of chest X-ray, and no evidence of prior (90 days) hospitalization/long-term care. We calculated incidence rates of adult CAP occurring in inpatient or outpatient VHA settings in 2011. We also estimated the proportion of VHA CAP patients who were hospitalized, were readmitted within 30 days of hospital discharge, and died (any cause) in the year following diagnosis. Incremental costs during the 90 days following a CAP diagnosis were estimated from the perspective of the VHA.
resultsIn 2011, 34,101 Veterans developed CAP (35,380 episodes) over 7,739,757 VHA person-years. Median age of CAP patients was 65 years (95 % male). CAP incidence rates were higher for those aged ≥50 years. A majority of Veterans aged 50-64 (53 %) and ≥65 (66 %) years had ≥1 chronic medical (moderate risk) or immunocompromising (high risk) condition. Compared to those at low-risk (healthy), moderate- and high-risk Veterans were >3 and >6 times more likely to develop CAP, respectively. The percentage of CAP patients who were hospitalized was 45 %, ranging from 12 % (age 18-49, low risk) to 57 % (age ≥65, high risk). One-year all-cause mortality rates ranged from 1 % (age 18-49, low risk) to 36 % (age ≥65, high risk). Annual VHA medical expenditure related to CAP was estimated to be $750 million (M) ($415M for those aged ≥65 years).
conclusionA focus on CAP prevention among older Veterans and those with comorbid or immunocompromising conditions is important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.